AKT2型
肺纤维化
博莱霉素
特发性肺纤维化
炎症
癌症研究
纤维化
下调和上调
医学
磷酸化
巨噬细胞
肺
基因敲除
小干扰RNA
免疫学
病理
化学
生物
AKT1型
核糖核酸
细胞生物学
内科学
细胞凋亡
蛋白激酶B
生物化学
体外
基因
化疗
作者
Yunjuan Nie,Lei Sun,Yaxian Wu,Yaoyao Yang,Jun Wang,Huiqiong He,Yudong Hu,Yanhua Chang,Qing Liang,Jianwei Zhu,Richard D. Ye,John William Christman,Feng Qian
出处
期刊:Journal of Immunology
[American Association of Immunologists]
日期:2017-04-29
卷期号:198 (11): 4470-4480
被引量:87
标识
DOI:10.4049/jimmunol.1601503
摘要
Abstract Idiopathic pulmonary fibrosis (IPF) is a highly lethal pathological process that is characterized by inflammation, fibroblast accumulation, and excessive collagen deposition. Although AKT2-mediated signaling pathways modulate inflammatory responses, their role in IPF has not been defined. We report that AKT2 deficiency (Akt2−/−) protected against bleomycin-induced pulmonary fibrosis and inflammation. Adoptive transfer of wild-type macrophages or administration of IL-13 to Akt2−/− mice could restore pulmonary fibrosis. In response to IL-33 treatment, Akt2−/− macrophages displayed decreased production of IL-13 and TGF-β1 and attenuated phosphorylation of FoxO3a compared with Akt2+/+ macrophages. Furthermore, the expression of IL-13 was increased by small interfering RNA knockdown of FoxO3a or in FoxO3a-deficient macrophages. By evaluating lung sections from pulmonary fibrosis patients, we found that the phosphorylation of AKT2 and FoxO3a was remarkably upregulated. Collectively, these results indicate that AKT2 modulates pulmonary fibrosis through inducing TGF-β1 and IL-13 production by macrophages, and inhibition of AKT2 may be a potential strategy for treating IPF.
科研通智能强力驱动
Strongly Powered by AbleSci AI